+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2025 - Product Thumbnail Image

Diffuse Cutaneous Systemic Sclerosis- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Prostaglandin Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Prostaglandin Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
C5a Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

C5a Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Glucocorticoid Induced Tumor Necrosis Factor - Pipeline Insight, 2025 - Product Thumbnail Image

Glucocorticoid Induced Tumor Necrosis Factor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chemokine Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Chemokine Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Interleukin-1 (IL-1) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
interleukin Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

interleukin Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 120 Pages
  • Global
From
Toll-Like Receptor Modulators - Pipeline Insight, 2025 - Product Thumbnail Image

Toll-Like Receptor Modulators - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 90 Pages
  • Global
From
Chronic Rhinosinusitis With Nasal Polyps - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Rhinosinusitis With Nasal Polyps - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Autoimmune Hepatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Autoimmune Hepatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Febrile Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chemotherapy Induced Neutropenia - Pipeline Insight, 2025 - Product Thumbnail Image

Chemotherapy Induced Neutropenia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Idiopathic Urticaria- Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Idiopathic Urticaria- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Rheumatoid Arthritis - Pipeline Insight, 2025 - Product Thumbnail Image

Rheumatoid Arthritis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 180 Pages
  • Global
From
Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025 - Product Thumbnail Image

Dystrophic Epidermolysis Bullosa - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 75 Pages
  • Global
From
Angioedema- Pipeline Insight, 2025 - Product Thumbnail Image

Angioedema- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Atopic Dermatitis - Pipeline Insight, 2025 - Product Thumbnail Image

Atopic Dermatitis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Pipeline Insight, 2025 - Product Thumbnail Image

Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Renal/Kidney Transplant Rejection - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Renal/Kidney Transplant Rejection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fibromyalgia - Pipeline Insight, 2025 - Product Thumbnail Image

Fibromyalgia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more